InvestorsHub Logo

DaubersUP

01/11/18 8:47 AM

#212326 RE: mantis #212325

It’s a constant ASPIRE drip.
It’s an unknown -NO analyst coverage stock
It’s an iHub stock


I’ve played the pennies, the otcbb the pinks etc..... financial pressure always rules the day and that is where you find the most undervalued bargain stocks .... during times of raising money.
Leo has decided to go the long term responsible drip way. No huge CDs or other extreme toxic route, he has slowly milked over 40 million in shares into the market over the past 6 years. And believe me....to pay for 8 human trials and pick up 10 additional compounds is unheard of for only 40 plus million shares.

Nonetheless, it’s a constant pressure.

The minute we get validation and a deal this will re-evaluate in a flash.

Leo will only license IMO. ATLEAST first. The value of the company is no where near true value.

Everything will change in a blink soon enough.

Imo

cabel

01/11/18 8:49 AM

#212327 RE: mantis #212325

Because Leo would not sell his company for that amount.

BP will pay what they think they can get back from the the market if the drug goes on the market,.. not a factor of the existing MC.

Good thing too,.. else the BP's would be involved in pushing down the price of all small bio-tech companies just so they can buy them cheaper.

Again they pay what they think they can get for the drug that the are buying,... and Leo and many ither CEO's would not accept a pittance buy-out.



BonelessCat

01/11/18 9:04 AM

#212332 RE: mantis #212325

A few exceptions? There are more than a dozen “exceptions” the past 5 years. Considering the number of acquisitions in that time, a dozen isn’t exceptional.